Search hospitals > Colorado > Denver
National Jewish Health
Claim this profileDenver, Colorado 80206
Global Leader in Fibrosis
Global Leader in Cystic Fibrosis
Conducts research for Asthma
Conducts research for Lung Disease
Conducts research for Pulmonary Fibrosis
474 reported clinical trials
26 medical researchers
Summary
National Jewish Health is a medical facility located in Denver, Colorado. This center is recognized for care of Fibrosis, Cystic Fibrosis, Asthma, Lung Disease, Pulmonary Fibrosis and other specialties. National Jewish Health is involved with conducting 474 clinical trials across 452 conditions. There are 26 research doctors associated with this hospital, such as Nicholas DiBella, Patrick Cobb, MD, Benjamin J. George, and Marwan Massouh.Area of expertise
1Fibrosis
Global LeaderCFTR
CFTR positive
F508del
2Cystic Fibrosis
Global LeaderCFTR
CFTR positive
F508del
Top PIs
Nicholas DiBellaRocky Mountain Cancer Centers-Boulder5 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
97 reported clinical trials
182 drugs studied
Patrick Cobb, MDSt. Vincent Frontier Cancer Center5 years of reported clinical research
Studies Breast Cancer
Studies Tumors
20 reported clinical trials
42 drugs studied
Benjamin J. GeorgeSCL Health Good Samaritan Medical Center Cancer Centers of Colorado5 years of reported clinical research
Studies Lymphoma
Studies Stomach Cancer
12 reported clinical trials
48 drugs studied
Marwan MassouhSaint James Community Hospital and Cancer Treatment Center6 years of reported clinical research
Studies Cancer
Studies Lung Cancer
11 reported clinical trials
35 drugs studied
Clinical Trials running at National Jewish Health
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Fibrosis
Pulmonary Fibrosis
Cystic Fibrosis
Bladder Cancer
Gastroesophageal Junction Adenocarcinoma
Gastric Cancer
Idiopathic Pulmonary Fibrosis
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at National Jewish Health?
National Jewish Health is a medical facility located in Denver, Colorado. This center is recognized for care of Fibrosis, Cystic Fibrosis, Asthma, Lung Disease, Pulmonary Fibrosis and other specialties. National Jewish Health is involved with conducting 474 clinical trials across 452 conditions. There are 26 research doctors associated with this hospital, such as Nicholas DiBella, Patrick Cobb, MD, Benjamin J. George, and Marwan Massouh.
Where is National Jewish Health located?
**National Jewish Health - Denver, Colorado**
- **Address:** 1400 Jackson Street, Denver, CO 80206. Located on the southwest corner of Colfax Avenue & Colorado Boulevard.
- **Parking:** Free valet, handicap, patient, and visitor parking available at the main entrance off Colfax Avenue.
Who should I call to ask about financial aid or insurance network?
**National Jewish Health Hospital Contact Information**
**Financial Assistance:**
- **Phone:** 303.398.1065
- **Email:** patientbusinessoffice@njhealth.org
- **In-person:** Financial Counseling office, main campus entrance.
**Insurance:**
- **Phone:** 1.800.423.8891 x1565 or 303.398.1565
- **Email:** patientbusinessoffice@njhealth.org
For general inquiries, including appointments, insurance, and billing, please contact 1.800.423.8891 x1565 or 303.398.1565.
What insurance does National Jewish Health accept?
National Jewish Health accepts a wide range of insurance plans for medical, dental, and vision coverage. Medical insurance options include Cigna Medical Insurance, Cigna SureFit $1000 Plan (Colorado Residents Only), Cigna Local Plus, and Cigna Open Access HDHP. Dental coverage is available through Cigna Dental Insurance, offering High PPO, Low PPO plans, and the DHMO plan, which requires using an in-network Cigna DHMO provider. Vision coverage is provided through VSP Vision Insurance, allowing enrollment in VSP Vision Care for care from a VSP network doctor at low out-of-pocket costs.
Additionally, National Jewish Health and its physicians participate with several managed care/insurance plans, including but not limited to AARP, Aetna Healthcare Inc., Anthem BlueCross BlueShield, Behavioral HealthCare, Inc., CIGNA Behavioral Health, Colorado Access, Coventry / First Health Network, Evercare, GEHA/PPO USA, Health First Colorado Medicaid, Humana Healthcare, Kaiser of Colorado, Magellan Behavioral Health, Medicare, Rocky Mountain Health Plans, TriCare, and United HealthCare.
What awards or recognition has National Jewish Health received?
National Jewish Health in Denver, Colorado, is the leading respiratory hospital in the nation, consistently ranked #1 or #2 in Pulmonology by U.S. News & World Report for 26 consecutive years. The hospital is celebrated for its groundbreaking research, notably the discovery of IgE, the molecule responsible for allergic reactions, and the development of the oral food challenge for diagnosing food allergies. It boasts a 95% patient recommendation rate and consistently receives high rankings in Press Ganey surveys, underscoring its excellence in patient care.